Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanil with or without dexketoprofen tromethamine for PCIA after thoracoscopic lung cancer surgery
ChiCTR2400087079Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sufentanil and dexketoprofen trometamol in postoperative pain (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Cumulative consumption of PCIA in the 48 hours after surgery. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
sufentanildexketoprofen trometamol
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400087079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087079.